目的：利用生物信息学研究微小RNA-4324（miR-4324）在卵巢癌中的表达情况，进一步分析miR-4324在卵巢癌发生、发展中的作用。方法：采用GEO数据库及GEO2R在线工具分析miR-4324在卵巢癌中的表达水平。用TargetScan数据库预测miR-4324的靶基因（TG-miR4324），并与从GEO数据库中筛选出的卵巢癌差异表达基因（DEGs）取交集，获得miR-4324相关性差异靶基因。运用DAVID数据库进行GO及KEGG富集分析，STRING数据库构建蛋白互作（PPI）网络，Cytoscape筛选hub基因，Kaplan-Meier Plotter分析hub基因对预后的影响。结果：卵巢癌组织中miR-4324表达下调。获得TG-miR4324共5 292个，其中筛选出290个miR-4324相关性差异靶基因，主要在细胞外基质、细胞黏附性、细胞外基质（ECM）受体的相互作用及癌症相关通路中富集。从miR-4324相关性差异靶基因中筛选出8个hub基因，其中SPSB1、TGOLN2等6个基因表达与卵巢癌患者的总生存期（OS）相关。结论：miR-4324在卵巢癌中表达下调，miR-4324相关性差异靶基因在卵巢癌生物学过程中起重要作用。

[1] BARTELD P.MicroRNAs:genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2):281-297.
[2] LI H L, ZHU G L, XING Y W, et al. miR-4324 functions as a tumor suppressor in colorectal cancer by targeting HOXB2[J]. J Int Med Res, 2020, 48(3):1219683283.
[3] INAMOTO T, UEHARA H, AKAO Ycet al. A panel of microRNA signature as a tool for predicting survival of patients with urothelial carcinoma of the bladder[J]. Dis Markers, 2018, 2018:5468672.
[4] 陈军莹, 姚德生, 贺婵娟, 等.宫颈鳞癌MicroRNA差异表达的研究[J]. 实用医学杂志, 2014, 30(1):83-87.
[5] SZKLARCZYK D, GABLE A L, LYON D, et al. STRING v11:protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets[J]. Nucleic Acids Res, 2019, 47(D1):D607-D613.
[6] SMOOT M E, ONO K, RUSCHEINSKI J, et al. Cytoscape 2.8:new features for data integration and network visualization[J]. Bioinformatics, 2011, 27(3):431-432.
[7] XU Z, ZHOU Y, CAO Y, et al. Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis[J]. Med Oncol, 2016, 33(11):130.
[8] LI S, HANG L, MA Y, et al. Distinctive microRNA expression in early stage nasopharyngeal carcinoma patients[J]. J Cell Mol Med, 2016, 20(12):2259-2268.
[9] ZHOU J, ZHU J, JIANG G, et al. Downregulation of microRNA-4324 promotes the EMT of esophageal squamous-cell carcinoma cells via upregulating FAK[J]. Onco Targets Ther, 2019, 12:4595-4604.
[10] WANG D Y, GENDOO D M A, BEN-DAVID Y, et al. A subgroup of microRNAs defines PTEN-deficient, triple-negative breast cancer patients with poorest prognosis and alterations in RB1, MYC, and Wnt signaling[J]. Breast Cancer Res, 2019, 21(1):18.
[11] LIU S, NHEU T, LUWOR R, et al. SPSB1, a novel negative regulator of the transforming growth factor-β signaling pathway targeting the type Ⅱ receptor[J]. J Biol Chem, 2015, 290(29):17894-17908.
[12] LIU S, IARIA J, SIMPSON R J, et al. Ras enhances TGF-β signaling by decreasing cellular protein levels of its type Ⅱ receptor negative regulator SPSB1[J]. Cell Commun Signal, 2018, 16(1):10.
[13] FENG Y, PAN T C, PANT D K, et al. SPSB1 promotes breast cancer recurrence by potentiating c-MET signaling[J]. Cancer Discov, 2014, 4(7):790-803.
[14] KIM H J, KIM M K, BAE M K, et al. SPSB1 enhances ovarian cancer cell survival by destabilizing p21[J]. Biochem Biophys Res Commun, 2019, 510(3):364-369.
[15] YOUNG A R, CHAN E Y, HU X W, et al. Starvation and ULK1-dependent cycling of mammalian Atg9 between the TGN and endosomes[J]. J Cell Sci, 2006, 119(Pt 18):3888-3900.
[16] KIHARA A, KABEYA Y, OHSUMI Y, et al. Beclin-phosphatidylinositol 3-kinase complex functions at the trans-Golgi network[J]. EMBO Rep, 2001, 2(4):330-335.
[17] 任松森, 吴松, 程萍.Beclin1通过调控自噬水平对卵巢癌细胞顺铂的敏感性干预效果及机制研究[J]. 中国性科学, 2020, 29(1):48-52.
[18] ZHANG S F, WANG X Y, FU Z Q, et al. TXNDC17 promotes paclitaxel resistance via inducing autophagy in ovarian cancer[J]. Autophagy, 2015, 11(2):225-238.